001package org.hl7.fhir.r4.model.codesystems;
002
003/*-
004 * #%L
005 * org.hl7.fhir.r4
006 * %%
007 * Copyright (C) 2014 - 2019 Health Level 7
008 * %%
009 * Licensed under the Apache License, Version 2.0 (the "License");
010 * you may not use this file except in compliance with the License.
011 * You may obtain a copy of the License at
012 * 
013 *      http://www.apache.org/licenses/LICENSE-2.0
014 * 
015 * Unless required by applicable law or agreed to in writing, software
016 * distributed under the License is distributed on an "AS IS" BASIS,
017 * WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
018 * See the License for the specific language governing permissions and
019 * limitations under the License.
020 * #L%
021 */
022
023
024/*
025  Copyright (c) 2011+, HL7, Inc.
026  All rights reserved.
027  
028  Redistribution and use in source and binary forms, with or without modification, 
029  are permitted provided that the following conditions are met:
030  
031   * Redistributions of source code must retain the above copyright notice, this 
032     list of conditions and the following disclaimer.
033   * Redistributions in binary form must reproduce the above copyright notice, 
034     this list of conditions and the following disclaimer in the documentation 
035     and/or other materials provided with the distribution.
036   * Neither the name of HL7 nor the names of its contributors may be used to 
037     endorse or promote products derived from this software without specific 
038     prior written permission.
039  
040  THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 
041  ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 
042  WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 
043  IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 
044  INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 
045  NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 
046  PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 
047  WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 
048  ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 
049  POSSIBILITY OF SUCH DAMAGE.
050  
051*/
052
053// Generated on Wed, Jan 30, 2019 16:19-0500 for FHIR v4.0.0
054
055
056import org.hl7.fhir.exceptions.FHIRException;
057
058public enum ResearchStudyPhase {
059
060        /**
061         * Trials without phases (for example, studies of devices or behavioral interventions).
062         */
063        NA, 
064        /**
065         * Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
066         */
067        EARLYPHASE1, 
068        /**
069         * Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
070         */
071        PHASE1, 
072        /**
073         * Trials that are a combination of phases 1 and 2.
074         */
075        PHASE1PHASE2, 
076        /**
077         * Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
078         */
079        PHASE2, 
080        /**
081         * Trials that are a combination of phases 2 and 3.
082         */
083        PHASE2PHASE3, 
084        /**
085         * Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
086         */
087        PHASE3, 
088        /**
089         * Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
090         */
091        PHASE4, 
092        /**
093         * added to help the parsers
094         */
095        NULL;
096        public static ResearchStudyPhase fromCode(String codeString) throws FHIRException {
097            if (codeString == null || "".equals(codeString))
098                return null;
099        if ("n-a".equals(codeString))
100          return NA;
101        if ("early-phase-1".equals(codeString))
102          return EARLYPHASE1;
103        if ("phase-1".equals(codeString))
104          return PHASE1;
105        if ("phase-1-phase-2".equals(codeString))
106          return PHASE1PHASE2;
107        if ("phase-2".equals(codeString))
108          return PHASE2;
109        if ("phase-2-phase-3".equals(codeString))
110          return PHASE2PHASE3;
111        if ("phase-3".equals(codeString))
112          return PHASE3;
113        if ("phase-4".equals(codeString))
114          return PHASE4;
115        throw new FHIRException("Unknown ResearchStudyPhase code '"+codeString+"'");
116        }
117        public String toCode() {
118          switch (this) {
119            case NA: return "n-a";
120            case EARLYPHASE1: return "early-phase-1";
121            case PHASE1: return "phase-1";
122            case PHASE1PHASE2: return "phase-1-phase-2";
123            case PHASE2: return "phase-2";
124            case PHASE2PHASE3: return "phase-2-phase-3";
125            case PHASE3: return "phase-3";
126            case PHASE4: return "phase-4";
127            default: return "?";
128          }
129        }
130        public String getSystem() {
131          return "http://terminology.hl7.org/CodeSystem/research-study-phase";
132        }
133        public String getDefinition() {
134          switch (this) {
135            case NA: return "Trials without phases (for example, studies of devices or behavioral interventions).";
136            case EARLYPHASE1: return "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.";
137            case PHASE1: return "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.";
138            case PHASE1PHASE2: return "Trials that are a combination of phases 1 and 2.";
139            case PHASE2: return "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.";
140            case PHASE2PHASE3: return "Trials that are a combination of phases 2 and 3.";
141            case PHASE3: return "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.";
142            case PHASE4: return "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.";
143            default: return "?";
144          }
145        }
146        public String getDisplay() {
147          switch (this) {
148            case NA: return "N/A";
149            case EARLYPHASE1: return "Early Phase 1";
150            case PHASE1: return "Phase 1";
151            case PHASE1PHASE2: return "Phase 1/Phase 2";
152            case PHASE2: return "Phase 2";
153            case PHASE2PHASE3: return "Phase 2/Phase 3";
154            case PHASE3: return "Phase 3";
155            case PHASE4: return "Phase 4";
156            default: return "?";
157          }
158    }
159
160
161}
162